Speed Medical results, Q2 2023
Net profit, assets, equity and cash flow for Q2 2023, against the same period a year earlier, from the published financial statements.
Net profit-24.82 millionEGP · +30.3% vs the same period a year earlier
Total assets566 millionEGP · −17.8% vs the same period a year earlier
Shareholders' equity232 millionEGP · −33.9% vs the same period a year earlier
Operating cash flow8.72 millionEGP · +195.7% vs the same period a year earlier
In short
- Speed Medical's net profit for Q2 2023 was about -24.82 million EGP, up +30.3% from -35.62 million EGP in Q2 2022.
- Total assets at the end of Q2 2023 were about 566 million EGP, and shareholders' equity about 232 million EGP.
- Operating cash flow for Q2 2023 was positive at 8.72 million EGP.
Key lines against the same period a year earlier
This periodQ2 2022Change
Net profit-24.82 million-35.62 million+30.3%
Gross profit-1.82 million-2.89 million+37.2%
Total assets566 million688 million−17.8%
Total liabilities333 million337 million−1.1%
Shareholders' equity232 million351 million−33.9%
Total liabilities and equity566 million688 million−17.8%
Operating cash flow8.72 million-9.11 million+195.7%
Investing cash flow-1.79 million-3.88 million+53.7%
Financing cash flow-7.55 million10.34 million−173.0%
Net change in cash-621 thousand-2.65 million+76.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Speed Medical's Q2 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy